Antisense oligonucleotide-induced inhibition of adrenocorticotropic hormone release from cultured human corticotrophs

Related Experiment Video

Updated: Oct 19, 2026

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions
04:33

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions

Published on: March 12, 2019

B Frankel1, S L Longo, G S Rodziewicz

  • 1Department of Neurosurgery, State University of New York Health Science Center at Syracuse, 13210, USA. frankelb@vax.cs.hscsyr.edu

Journal of Neurosurgery
|August 5, 1999
PubMed
Abstract

Insights

New antisense oligonucleotide therapies show promise for treating Cushing's disease by significantly reducing adrenocorticotropic hormone (ACTH) release. This novel approach targets a key problem in the condition, offering potential for improved patient outcomes.

Area of Science:

  • Endocrinology
  • Molecular Medicine
  • Pharmacology

Background:

  • Cushing's disease therapies are often inadequate, particularly for cases involving corticotroph hyperplasia.
  • Novel treatments are needed to address the challenges posed by existing therapeutic options.

Purpose of the Study:

  • To investigate the efficacy of phosphorothioate antisense oligonucleotides as a potential treatment for Cushing's disease.
  • To evaluate the impact of these oligonucleotides on adrenocorticotropic hormone (ACTH) secretion.

Main Methods:

  • Corticotrophs from a Cushing's disease patient were cultured in vitro.
  • Antisense oligonucleotides targeting the ACTH-coding region of the proopiomelanocortin precursor were synthesized.
  • Liposome-coated oligonucleotides were used to treat cultured corticotrophs, and ACTH release was measured.

Main Results:

  • Cultured corticotrophs exhibited autonomous growth and ACTH secretion.
  • Treatment with antisense oligonucleotides resulted in a >90% decrease in ACTH release by Days 3 and 6 (p < 0.05).

Conclusions:

  • Antisense oligonucleotides demonstrate potential as an effective adjunct therapy for Cushing's disease.
  • Targeting ACTH hypersecretion with antisense oligonucleotides addresses a fundamental aspect of the disease.

More Related Videos

Establishment of Zone-Enriched Primary Cultures from the Mouse Adrenal Cortex07:43

Establishment of Zone-Enriched Primary Cultures from the Mouse Adrenal Cortex

Published on: May 8, 2026

Related Concept Videos

Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Hypothalamic-Pituitary Axis01:37

Hypothalamic-Pituitary Axis

The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor.
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Hormones of the Adrenal Glands01:31

Hormones of the Adrenal Glands

Adrenal hormones play a pivotal role in maintaining the body's electrolyte balance and orchestrating responses to stress, showcasing the intricate functions of the adrenal cortex and medulla.
The adrenal cortex, a powerhouse of hormone synthesis, generates over two dozen corticosteroid hormones. The zona glomerulosa produces mineralocorticoids, exemplified by aldosterone, influencing the electrolyte composition of body fluids. The synthesis of glucocorticoids such as cortisol and corticosterone...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...